peptidylarginine deiminase

GSK484 hydrochloride (GTPL8577) 是一种可逆的肽酰基精氨酸脱亚氨酶 4 (PAD4) 抑制剂。它高亲和力与 PAD4 结合，在存在 2 mM 钙和不存在钙的情况下，IC50分别为 250 和 50 nM。GSK484 可以在体内和体外促进结直肠癌（CRC）的放射敏感性并抑制 NET 的形成。

Acefylline (Theophylline-7-acetic acid) 是黄嘌呤衍生物，是一种腺苷受体拮抗剂。它是蛋白质精氨酸脱亚氨酶 (PAD) 激活剂，也是一种支气管扩张剂，可抑制大鼠肺 cAMP 磷酸二酯酶同工酶。

Cl-amidine hydrochloride 是一种口服有效的PAD抑制剂，可阻断组蛋白3去亚胺化和中性粒细胞胞外陷阱的形成，并提高败血症小鼠的存活率。它可诱导癌细胞凋亡，还可诱导 miR-16 引起细胞周期阻滞。

GSK199 是可逆的 PAD4选择性抑制剂，当缺少钙离子时，其 IC50值为 200 nM。

BMS-P5 是一种特异性具有口服活性的肽精氨酸二亚胺酶 4抑制剂。它可阻断多发性骨髓瘤诱导的 NET 形成，并延缓肿瘤进程。

BMS-P5 free base 是一种特异性，可口服的肽精氨酸二亚胺酶抑制剂，可阻断多发性骨髓瘤诱导的 NET 形成，并延缓肿瘤进程。

GSK121 Trifluoroacetate 是PAD4的选择性抑制剂。

YW3-56 is a potent peptidylarginine deiminase (PAD) inhibitor, with an IC50 of 1-5 μM for PAD4. Compared with Cl-amidine, YW3-56 shows >60-fold increase in cell growth inhibition efficacy (IC50 about 2.5 μM) but only 5-fold increase in PAD4 inhibition (IC sub>50 about 1-5 μM). At 2-4 μM concentrations, YW3-56 displays mainly cytostatic effects by slowing cell division, whereas at higher concentrations, it exerts cytotoxic effects by altering cell morphology and killing cells[1]. [1]. Wang Y, et al. Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and t he mammalian target of rapamycin complex 1 activity. J Biol Chem. 2012 Jul 27;287(31):25941-53.

YW3-56 is an inhibitor of protein arginine deiminase 2 (PAD2) and PAD4 (IC50s = 0.5-1 and 1-5 μM, respectively).1It inhibits the growth of U2OS osteosarcoma cells (IC50= ~2.5 μM) in a p53-dependent mannerviainduction of SESN2 and subsequent inhibition of mTORC1. YW3-56 (10 mg kg) reduces tumor growth in an S-180 murine sarcoma tumor model. It also inhibits tumor growth in the 1883 MDA-MB-231 breast cancer bone metastasis mouse xenograft model.2 1.Wang, Y., Li, P., Wang, S., et al.Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activityThe Journal of Biological Chemisty287(31)25941-25952(2012) 2.Wang, S., Chen, X.A., Hu, J., et al.ATF4 gene network mediates cellular response to the anticancer PAD inhibitor YW3-56 in triple-negative breast cancer cellsMol. Cancer Ther.14(4)877-888(2015)